|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
3
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
4
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
5